Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer
Gynecologic Oncology May 24, 2019
Chapman BV, et al. - Via this retrospective analysis of 249 women with FIGO 2009 stage IIIC endometrial cancer, researchers sought to determine the optimal adjuvant treatment regimen for cases with endometrioid and non-endometrioid node-positive endometrial cancer. The participants had undergone surgical staging followed by treatment with external beam radiotherapy (RT), chemotherapy (CT), or a combination of CT + RT. The Kaplan-Meier method was used to calculate survival rates. In patients with all subtypes of node-positive endometrial cancer, excellent outcomes were obtained with combined-modality therapy including adjuvant external beam pelvic radiotherapy. In women with non-endometrioid endometrial cancer, adjuvant chemoradiotherapy offered the most pronounced disease-specific survival benefit.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries